Published in Drug Week, April 6th, 2001
This first-time publication of detailed Phase II data in a peer-reviewed journal shows that on-demand treatment with Cialis, an advanced phosphodiesterase type 5 (PDE5) inhibitor, improved erections in 81% of men (relative to placebo: 17%), regardless of severity. Cialis is currently in global Phase III studies.
"Cialis is a potent and highly selective PDE5 inhibitor that both increased sexual function and was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.